Abstract
We have further defined mechanism(s) by which the drug OSU-03012 (OSU) kills brain cancer cells. OSU toxicity was enhanced by the HSP90 inhibitor 17-N-Allylamino-17-demethoxygeldanamycin (17AAG) that correlated with reduced expression of ERBB1 and ERBB2. Inhibition of the extrinsic apoptosis pathway blocked the interaction between 17AAG and OSU. OSU toxicity was enhanced by the inhibitor of ERBB1/2/4, lapatinib. Knock down of ERBB1/2/4 in a cell line specific fashion promoted OSU toxicity. Combined exposure of cells to lapatinib and OSU resulted in reduced AKT and ERK1/2 activity; expression of activated forms of AKT and to a lesser extent MEK1 protected cells from the lethal effects of the drug combination. Knock down of PTEN suppressed, and expression of PTEN enhanced, the lethal interaction between OSU and lapatinib. Downstream of PTEN, inhibition of mTOR recapitulated the effects of lapatinib. Knock down of CD95, NOXA, PUMA, BIK or AIF, suppressed lapatinib and OSU toxicity. Knock down of MCL-1 enhanced, and overexpression of MCL-1 suppressed, drug combination lethality. Lapatinib and OSU interacted in vivo to suppress the growth of established tumors. Collectively our data argue that the inhibition of ERBB receptor function represents a useful way to enhance OSU lethality in brain tumor cells.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Apoptosis / drug effects*
-
Apoptosis Regulatory Proteins / genetics
-
Autophagy-Related Protein 5
-
Beclin-1
-
Benzoquinones / pharmacology
-
Brain Neoplasms / drug therapy*
-
Celecoxib
-
Cell Line, Tumor
-
Drug Synergism
-
Endoplasmic Reticulum Chaperone BiP
-
ErbB Receptors / genetics
-
Genes, erbB-1
-
Heat-Shock Proteins / genetics
-
Humans
-
Lactams, Macrocyclic / pharmacology
-
Lapatinib
-
Lipids
-
MAP Kinase Kinase 1
-
Membrane Proteins / genetics
-
Microtubule-Associated Proteins / genetics
-
Myeloid Cell Leukemia Sequence 1 Protein
-
PTEN Phosphohydrolase / genetics
-
Proto-Oncogene Proteins c-akt / drug effects
-
Proto-Oncogene Proteins c-akt / metabolism
-
Proto-Oncogene Proteins c-bcl-2 / genetics
-
Pyrazoles / pharmacology*
-
Quinazolines / pharmacology*
-
RNA Interference
-
RNA, Small Interfering
-
Receptor, ErbB-2 / antagonists & inhibitors
-
Receptor, ErbB-4
-
Signal Transduction / drug effects
-
Sulfonamides / pharmacology*
Substances
-
ATG5 protein, human
-
Apoptosis Regulatory Proteins
-
Autophagy-Related Protein 5
-
BECN1 protein, human
-
Beclin-1
-
Benzoquinones
-
Endoplasmic Reticulum Chaperone BiP
-
Heat-Shock Proteins
-
Lactams, Macrocyclic
-
Lipids
-
Lipofectamine
-
Membrane Proteins
-
Microtubule-Associated Proteins
-
Myeloid Cell Leukemia Sequence 1 Protein
-
OSU 03012
-
Proto-Oncogene Proteins c-bcl-2
-
Pyrazoles
-
Quinazolines
-
RNA, Small Interfering
-
Sulfonamides
-
Lapatinib
-
tanespimycin
-
ERBB2 protein, human
-
ERBB4 protein, human
-
ErbB Receptors
-
Receptor, ErbB-2
-
Receptor, ErbB-4
-
Proto-Oncogene Proteins c-akt
-
MAP Kinase Kinase 1
-
MAP2K1 protein, human
-
PTEN Phosphohydrolase
-
PTEN protein, human
-
Celecoxib